Mel Hayes
Corporate Officer/Principal bij FULCRUM THERAPEUTICS, INC.
Vermogen: 47 614 $ op 30-04-2024
Profiel
Mel Hayes is currently the Executive Vice President-Patient Experience at Fulcrum Therapeutics, Inc. Prior to this, he held positions at Genzyme Corp., Bioverativ, Inc., Shire, Inc., Sanofi Ventures, and Baxalta, Inc. His former roles include VP-Rare Blood Disorders & Global Head-Commercial, Vice President-Hemophilia, and Global VP & Head-Global Marketing.
Mr. Hayes completed his undergraduate degree at Southern Methodist University and holds an MBA from Columbia Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2024 | 6 678 ( 0.01% ) | 47 614 $ | 30-04-2024 |
Actieve functies van Mel Hayes
| Bedrijven | Functie | Begin |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Corporate Officer/Principal | 02-10-2023 |
Eerdere bekende functies van Mel Hayes
| Bedrijven | Functie | Einde |
|---|---|---|
| BAXALTA INC | Corporate Officer/Principal | - |
Shire, Inc.
 Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The private company is based in Lexington, KY. | Sales & Marketing | - |
Sanofi Ventures
 Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Corporate Officer/Principal | - |
| BIOVERATIV INC | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Opleiding van Mel Hayes
| Southern Methodist University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Shire, Inc.
Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The private company is based in Lexington, KY. | Health Technology |
